Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244419 | PMC |
| http://dx.doi.org/10.1016/j.ihj.2020.05.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.
Nat Cancer
January 2025
Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Cancer Cluster Salzburg, Salzburg, Austria.
The role of anthracyclines in the treatment of early breast cancer (EBC) is increasingly being challenged, especially in de-escalation strategies. However, owing to their immunogenic effects, anthracyclines are promising combination partners with immunotherapies. In the randomized phase 2 trial ABCSG-52 (EudraCT no.
View Article and Find Full Text PDFLong-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study.
Eur J Surg Oncol
January 2025
Karolinska Institutet, Oncology/Pathology Department, Stockholm, Sweden; Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden. Electronic address:
Introduction: Although neoadjuvant systemic treatment for non-metastatic breast cancer has gained ground during the past decade, there is no compelling evidence that it improves overall survival compared to primary tumor resection and adjuvant treatment. At the same time, the approach to responders to neoadjuvant treatment in the axilla is evolving.
Materials And Methods: This is a retrospective analysis of a prospectively collected population-based registry.
Current and emerging treatment options for BRAFV600-mutant melanoma.
Expert Rev Anticancer Ther
January 2025
Skin and Renal Unit, Royal Marsden Hospital, London, United Kingdom.
Introduction: BRAF mutations are the most common driver mutation in cutaneous melanoma, present in 40% of cases. Rationally designed BRAF targeted therapy (TT) has been developed in response to this, and alongside immune checkpoint inhibitors (ICI), forms the backbone of systemic therapy options for BRAF-mutant melanoma. Various therapeutic approaches have been studied in the neoadjuvant, adjuvant and advanced settings, and there is a wealth of information to guide clinicians managing these patients.
View Article and Find Full Text PDFTreatment Strategies in Elderly Patients With Operable, Hormone Receptor-negative Breast Cancer.
Cancer Diagn Progn
January 2025
Department of Breast and Endocrine Surgery, Mitsui Memorial Hospital, Tokyo, Japan.
Background/aim: Elderly patients with early-stage breast cancer have potentially been underrepresented in clinical trials. Thus, treatment strategies for a minority of elderly patients with hormone receptor (HR)-negative breast cancer may be inadequately informed.
Patients And Methods: We retrospectively reviewed 126 patients with HR-negative breast cancer aged ≥65 years.
De-escalation of surgical and radiation treatment in elderly luminal breast cancer patients, single institution report and review of the evidence.
World J Surg Oncol
January 2025
Institute of Oncology, Tel Aviv Sourasky Medical Center, Weizmann St 6, Tel Aviv, Israel.
Background: De-intensification of anti-cancer therapy without significantly affecting outcomes is an important goal. Omission of axillary surgery or breast radiation is considered a reasonable option in elderly patients with early-stage breast cancer and good prognostic factors. Data on avoidance of both axillary surgery and radiation therapy (RT) is scarce and inconclusive.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!